2025
Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation
Amoako K, Mokhammad A, Malik A, Yesudasan S, Wheba A, Olagunju O, Gu S, Yarovinsky T, Faustino E, Nguyen J, Hwa J. Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation. Frontiers In Medical Technology 2025, 7: 1591119. PMID: 40589473, PMCID: PMC12206802, DOI: 10.3389/fmedt.2025.1591119.Peer-Reviewed Original ResearchNucleic acid deliveryLipid nanoparticlesAcid deliveryDesign of lipid nanoparticlesMessenger RNADeliver messenger RNAEnhancing nucleic acid deliveryLipid nanoparticle formulationImmune response modulationHematologic therapyPlatelet-related disordersNucleic acid cargoHematological treatmentNanoparticle formulationGold standardEndosomal trappingTherapeutic potentialPersonalized medicineDelivery efficiencyNanoparticle designPlateletCellular targetsResponse modulationDeliveryTransfection barriersTechnology Spotlight New Dimensions for Platelet Evaluation in Hematology Diagnostics
Gu S, Bona R, Hwa J. Technology Spotlight New Dimensions for Platelet Evaluation in Hematology Diagnostics. The Hematologist 2025, 22 DOI: 10.1182/hem.v22.3.202538.Peer-Reviewed Original Research
2024
Demographic diversity in platelet function and response to antiplatelet therapy
Jain K, Tyagi T, Gu S, Faustino E, Hwa J. Demographic diversity in platelet function and response to antiplatelet therapy. Trends In Pharmacological Sciences 2024, 46: 78-93. PMID: 39672782, PMCID: PMC11710996, DOI: 10.1016/j.tips.2024.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsResponse to antiplatelet therapyCardiovascular diseaseAntiplatelet therapyPlatelet biologyPathological platelet activationCardiovascular disease riskNon-genetic factorsPopulation-based differencesAntiplatelet strategiesPlatelet functionCardiovascular outcomesDiverse rolesPlatelet activationTherapeutic approachesTherapyPlateletBiologyFully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency
Park J, Riaz M, Qin L, Zhang W, Batty L, Fooladi S, Kural M, Li X, Luo H, Xu Z, Wang J, Banno K, Gu S, Yuan Y, Anderson C, Ellis M, Zhou J, Luo J, Shi X, Shin J, Liu Y, Lee S, Yoder M, Elder R, Mak M, Thorn S, Sinusas A, Gruber P, Hwa J, Tellides G, Niklason L, Qyang Y. Fully biologic endothelialized-tissue-engineered vascular conduits provide antithrombotic function and graft patency. Cell Stem Cell 2024, 32: 137-143.e6. PMID: 39644899, PMCID: PMC11698629, DOI: 10.1016/j.stem.2024.11.006.Peer-Reviewed Original ResearchTissue-engineered vascular conduitsSingle-ventricle congenital heart defectsEndothelial cellsBiodegradable polymeric scaffoldsGraft patencyAutologous bone marrow cellsAntithrombotic functionCongenital heart defectsInferior vena cava graftHiPSC-derived endothelial cellsBone marrow cellsHuman umbilical arteryDecellularized human umbilical arteriesPolymeric scaffoldsHost endothelial cellsHuman induced pluripotent stem cell (hiPSC)-derived endothelial cellsUmbilical arteryHeart defectsVascular conduitsMarrow cellsFlow bioreactorVena cava graftNude ratsGraft stenosisClinical trialsHigh-Dimensional Single-Cell Mass Cytometry Demonstrates Differential Platelet Functional Phenotypes in Infants With Congenital Heart Disease
Gu S, Marcus B, Gu V, Varghese A, Hwa J, Faustino E. High-Dimensional Single-Cell Mass Cytometry Demonstrates Differential Platelet Functional Phenotypes in Infants With Congenital Heart Disease. Arteriosclerosis Thrombosis And Vascular Biology 2024, 44: 2530-2539. PMID: 39171400, PMCID: PMC11602369, DOI: 10.1161/atvbaha.124.321131.Peer-Reviewed Original ResearchCongenital heart diseaseNon-CHD controlsSubpopulation of plateletsCytokine analysisAssociated with congenital heart diseaseSurface markersPlatelet activationHeart diseaseAssociated with hematological abnormalitiesChildren's Heart CenterPlasma cytokine analysisComplex heart defectsBlood of infantsThrombotic vascular complicationsIL (interleukin)-6Cell surface markersDecreased platelet activationMass cytometry approachPlatelet surface markersHypogranular plateletsHeart defectsBleeding eventsPlasma cytokinesPlatelet function phenotypesInflammatory markers
2023
Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders
Gu S, Gallagher P, Butt A, Gu V, Lezon-Geyda K, Schulz V, Prozora S, Lee A, Neparidze N, Bar N, Martin K, Cornell J, Chirico G, Chakraborty R, Rinder H, Hwa J, Bona R. Multimodality Platelet Evaluation By Mass Cytometry and Genetic Analysis in Patients with Bleeding Disorders. Blood 2023, 142: 1197. DOI: 10.1182/blood-2023-177946.Peer-Reviewed Original ResearchBleeding tendencyBleeding disorderPlatelet markersPlatelet aggregometryMass cytometryPlatelet functionPlatelet disordersSingle-center prospective studyLow-risk groupAbnormal bleeding tendencyQualitative platelet disordersLarge patient cohortQuantitative platelet disordersCommon underlying causeGenetic variantsMultimodality evaluationTotal patientsRisk stratificationLaboratory suspicionPlatelet dysfunctionProspective studyPatient cohortUnivariate analysisPlatelet volumeRisk groupsFishing for “complements” with vascular organoid models of microvascular disease
Gu S, Yarovinsky T, Hwa J. Fishing for “complements” with vascular organoid models of microvascular disease. Cell Stem Cell 2023, 30: 1285-1286. PMID: 37802032, DOI: 10.1016/j.stem.2023.09.004.Commentaries, Editorials and LettersInsights into platelet pharmacology from a cryo-EM structure of the ABCC4 transporter
Sharda A, Gu S, Hwa J. Insights into platelet pharmacology from a cryo-EM structure of the ABCC4 transporter. Nature Cardiovascular Research 2023, 2: 606-608. PMID: 37655224, PMCID: PMC10470688, DOI: 10.1038/s44161-023-00293-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSOD2 in platelets: with age comes responsibility
Jain K, Gu S, Hwa J. SOD2 in platelets: with age comes responsibility. Journal Of Thrombosis And Haemostasis 2023, 21: 1077-1081. PMID: 36716965, DOI: 10.1016/j.jtha.2023.01.016.Commentaries, Editorials and Letters
2022
Plasma Proteomic Profiling Illustrates Endothelial and Complement Signature in Patients with Alcohol-Associated Cirrhosis
Allen C, Butt A, Zhao X, Li F, Bahel P, Chang C, Chun H, Gu S, Hwa J, Jakab S, Chen B, Garcia-Tsao G, Rinder H, To U, McConnell M, Lee A, Pine A. Plasma Proteomic Profiling Illustrates Endothelial and Complement Signature in Patients with Alcohol-Associated Cirrhosis. Blood 2022, 140: 8382-8383. DOI: 10.1182/blood-2022-162633.Peer-Reviewed Original ResearchA guide to molecular and functional investigations of platelets to bridge basic and clinical sciences
Tyagi T, Jain K, Gu S, Qiu M, Gu V, Melchinger H, Rinder H, Martin K, Gardiner E, Lee A, Tang W, Hwa J. A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. Nature Cardiovascular Research 2022, 1: 223-237. PMID: 37502132, PMCID: PMC10373053, DOI: 10.1038/s44161-022-00021-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsVascular smooth muscle cellsPlatelet functional assaysCoronavirus disease 2019Smooth muscle cellsImmune cellsImmune regulationVascular remodelingDisease 2019Pathophysiological processesTranslational relevancePatient diagnosisFlow cytometryMuscle cellsPlatelet biologyFunctional assaysPlatelet investigationsHomeostatic processesPlateletsPhenotypic heterogeneityFunctional stateClinical scienceCellsAdditional roleThrombosisSuch diverse functions
2020
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation
Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI, Halene S, Martin KA, Chun HJ, Hwa J. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews Cardiology 2020, 18: 194-209. PMID: 33214651, PMCID: PMC7675396, DOI: 10.1038/s41569-020-00469-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdministration, InhalationAnticoagulantsBlood Coagulation DisordersBlood Platelet DisordersCOVID-19COVID-19 Drug TreatmentEndothelium, VascularEndothelium-Dependent Relaxing FactorsEpoprostenolHeart Disease Risk FactorsHumansIloprostInflammationNitric OxidePlatelet Aggregation InhibitorsSARS-CoV-2Systemic Inflammatory Response SyndromeThrombosisThrombotic MicroangiopathiesVascular DiseasesVasodilator AgentsVenous ThromboembolismConceptsCardiovascular risk factorsRisk factorsCOVID-19Severe acute respiratory syndrome coronavirus 2Pre-existing cardiovascular diseaseAcute respiratory syndrome coronavirus 2Traditional cardiovascular risk factorsAcute respiratory distress syndromeRespiratory syndrome coronavirus 2Respiratory distress syndromeManagement of patientsSyndrome coronavirus 2COVID-19 pathologyCoronavirus disease 2019Potential therapeutic strategyCytokine stormEndothelial dysfunctionThrombotic complicationsDistress syndromeExcessive inflammationCoronavirus 2Severe outcomesAdvanced ageCardiovascular diseaseDisease 2019
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply